This study investigated whether namilumab, a granulocyte-macrophage colony-stimulating factor inhibitor, might improve outcomes in patients with moderate or severe plaque psoriasis.
The British Journal of Dermatology
Original Article: GM-CSF as a Therapeutic Target in Psoriasis